Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
Ovarian Cancer Expansion Cohort: Histologically or cytologically confirmed, epithelial ovarian, fallopian tube, or peritoneal cancer.
* Checkpoint inhibitor naive participants.
* Willing to consent to 1 mandatory pre-treatment and 1 on-treatment tumor biopsy.
Adequate performance status. Adequate hematological, liver, and kidney functions.
Availability of pre-treatment tumor tissue to evaluate programmed cell death-ligand 1(PD-L1) expression.
You may not be if
Individuals with symptomatic or untreated central nervous system (CNS) metastases.
Prior treatment with cluster of differentiation 47 (CD47) or signal regulatory protein alpha (SIRPα) targeting agents.
Known active or chronic hepatitis B or C infection or human immunodeficiency virus (HIV).
Red blood cell transfusion dependence.
Prior organ transplantation requiring immunosuppression or active autoimmune disease.
Significant medical diseases and/or history of uncontrolled intercurrent illness or other serious medical condition.
Pregnancy or active breast feeding.
Clareo Health | Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
